- Home
- AQST vs FDMT Comparison
AQST vs FDMT Comparison
Compare AQST & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | FDMT |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | 142 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.0M | 513.6M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AQST | FDMT |
|---|---|---|
| Price | $4.07 | $8.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $9.00 | ★ $32.40 |
| AVG Volume (30 Days) | ★ 2.0M | 682.5K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,430,000.00 | $37,000.00 |
| Revenue This Year | $14.23 | $21,227.03 |
| Revenue Next Year | $58.36 | $161.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.20 | $2.24 |
| 52 Week High | $7.55 | $12.34 |
Technical Indicators
Market Signals| Indicator | AQST | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 43.04 |
| Support Level | $3.69 | $8.11 |
| Resistance Level | $4.46 | $8.80 |
| Average True Range (ATR) | 0.21 | 0.56 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 30.09 | 11.35 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.